Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data

SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment...